IFF flavor 316 282, Paracetamol , Phenylephrine, Guaifenesin

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Upper Respiratory Infections

Conditions

Upper Respiratory Infections

Trial Timeline

Mar 1, 2012 → May 1, 2012

NCT ID

NCT01576809

About IFF flavor 316 282, Paracetamol , Phenylephrine, Guaifenesin

IFF flavor 316 282, Paracetamol , Phenylephrine, Guaifenesin is a phase 3 stage product being developed by Novartis for Upper Respiratory Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT01576809. Target conditions include Upper Respiratory Infections.

What happened to similar drugs?

6 of 14 similar drugs in Upper Respiratory Infections were approved

Approved (6) Terminated (1) Active (8)

✅Remimazolam TosilateJiangsu Hengrui MedicineApproved

✅BOTOXAbbVieApproved

✅Montelukast + PlaceboMerckApproved

✅diclofenac potassium + nimesulideNovartisApproved

✅Diclofenac gelNovartisApproved

✅AboBoNT-A + OnaBoNT-AIpsenApproved

🔄Muntelukast + PlaceboMerckPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01576809	Phase 3	Completed	Mar 1, 2012	May 1, 2012	Upper Respiratory Infections

Competing Products

20 competing products in Upper Respiratory Infections

See all competitors

Product	Company	Stage	Hype Score
Nivolumab 100 MG in 10 ML Injection	Ono Pharmaceutical	Phase 2	31
Remimazolam Tosilate	Jiangsu Hengrui Medicine	Approved	43
ABBV-950 + BOTOX + Placebo for ABBV-950	AbbVie	Phase 1	21
BOTOX + Placebo for BOTOX	AbbVie	Phase 2	35
BOTOX	AbbVie	Approved	43
MK-3475 and BCG	Merck	Phase 2	42
Montelukast + Placebo	Merck	Approved	43
Muntelukast + Placebo	Merck	Phase 3	36
IFF flavor 316 282, Paracetamol, Pseudoephedrine	Novartis	Phase 3	40
Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets + Paracetamol (500 mg) tablets	Novartis	Phase 3	40
diclofenac potassium + nimesulide	Novartis	Approved	35
Diclofenac gel	Novartis	Approved	43
Domvanalimab + Zimberelimab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin + Nivolumab	Gilead Sciences	Phase 3	44
Azithromycin SR	Pfizer	Phase 3	40
Nivolumab	Bristol Myers Squibb	Pre-clinical	26
Nivolumab	Bristol Myers Squibb	Pre-clinical	26
REGN475/SAR164877 + Placebo (for REGN475/SAR164877)	Regeneron Pharmaceuticals	Phase 2	27
IPN10200 + IPN10200 Placebo + Dysport	Ipsen	Phase 1/2	36
AboBoNT-A + OnaBoNT-A	Ipsen	Approved	40
Botulinum toxin type A	Ipsen	Phase 3	37